Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by SizzlinSteakson Aug 30, 2018 9:48am

106 Views

Post# 28541710

RE:RE:Let's roll

No lack of sellers...that's for sure!

Level ll Quote for KALYTERA THERAPEUTICS INC (KALY: TSX Venture)

Bid			Ask
Price	Total Size	# of Orders	Price	Total Size	# of Orders
$0.09	1289000	21	$0.10	1097000	28
$0.085	948000	39	$0.105	744000	10
$0.08	1076000	46	$0.11	455000	15
$0.075	124000	11	$0.115	219000	6
$0.07	135000	8	$0.12	327000	10
$0.065	106000	7	$0.125	254000	7
$0.06	102000	8	$0.13	303000	9
$0.055	202000	4	$0.135	96000	4
$0.05	107000	9	$0.14	211000	5
$0.045	16000	3	$0.145	17000	1